[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-372622-105":59,"doc-detail-372622-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","microbiome-modulation-for-the-treatment-of-solid-neoplasms","Microbiome Modulation for the Treatment of Solid Neoplasms","","Microbiome modulation is increasingly explored as an oncology therapeutic strategy, driven by links between the human gut microbiome and immune responses. Preclinical and clinical evidence associates specific stool taxa—such as Ruminococcaceae, Akkermansia, and Bifidobacterium—with improved outcomes to immune checkpoint inhibitors (ICIs). Antibiotic-driven disruption correlates with resistance and reduced survival. Biomarkers like TOPOSCORE aim to predict ICI benefit and dysbiosis, while dietary fiber, select probiotics, and fecal microbiota transplantation show early promise. The field still requires large randomized trials to establish standards of care.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/microbiome-modulation-for-the-treatment-of-solid-neoplasms/372622/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/microbiome-modulation-for-the-treatment-of-solid-neoplasms/372622.png","ImageObject",300,407,{"name":92,"@type":93},"supergirl","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":56},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How does gut microbiome modulation relate to immune checkpoint inhibitor outcomes in solid tumors?","Question",{"text":112,"@type":113},"The review links gut microbiome composition to immune system behavior that influences responses to ICIs. Favorable bacterial taxa correlate with better treatment responses, while disruption can worsen outcomes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which stool bacterial groups are associated with improved clinical outcomes to ICIs?",{"text":117,"@type":113},"Ruminococcaceae, Akkermansia, and Bifidobacterium are described as correlating with favorable clinical outcomes. Additional trial data also connect genera such as Sutterella with responder status in some settings.",{"name":119,"@type":110,"acceptedAnswer":120},"What microbiome-modulating strategies are discussed, and what limitations remain?",{"text":121,"@type":113},"The review covers fecal microbiota transplantation, probiotics, prebiotics, and related interventions, including their mechanisms. It highlights limitations such as variable responses, lack of universally accepted dosing for prebiotics, possible overgrowth of nonbeneficial bacteria, and risks tied to transplantation.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},372622,1790273896,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":56,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":29,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144},962088121634,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Review Articles  \nMicrobiome Modulation for the Treatment of Solid Neoplasms  \nRegina Barragan-Carrillo, MD1,2 ; Zeynep B. Zengin, MD3; and Sumanta K. Pal, MD1  DOI [https://doi.org/10.1200/JCO-25-00374](https://doi.org/10.1200/JCO-25-00374)  \nABSTRACT  \nThe interplay between the human gut microbiome and the immune system has sparked growing interest in microbiome modulation as a therapeutic strategy in oncology. Preclinical studies have identified specific bacterial species linked to improved responses to immune checkpoint inhibitors (ICIs), leading to clinical investigations in melanoma, renal cell carcinoma (RCC), and non–small cell lung cancer (NSCLC) . The stool bacterial abundance of Ruminococcaceae, Akkermansia, and Bifidobacterium correlates with favorable clinical outcomes, whereas the disruption of the gut microbiome through antibiotics before or during ICI initiation is associated with higher rates of primary resistance and shorter survival. Biomarkers such as TOPOSCORE have been developed to better predict ICI benefits and estimate dysbiosis and treatment responses. Several microbiome-modulating strategies have shown potential inpatients receiving treatment with ICIs—for instance, high dietary fiber intake maybe linked to improved outcomes. As a separate strategy, certain probiotics appear to enhance clinical activity in early trials when incorporated into ICI-based regimens. Finally, fecal microbiota transplantation has shown safety and efficacy in ICI-refractory melanoma and yielded encouraging results in treatment-nave patients with melanoma, NSCLC, and RCC. Although several compelling signals have been observed to date with microbiome manipulation, the fieldis lacking large, definitive randomized trials—these are indeed a prerequisite for any of the highlighted strategies to become a standard of care.  \nAccepted May 28, 2025 Published July 11, 2025  \nJ Clin Oncol 43:2734-2738 © 2025 by American Society of Clinical Oncology  \nView Online Article  \nCreative Commons Attribution Non-Commercial No Derivatives 4.0 License  \nThe human microbiome is an ecosystem of microorganisms composed primarily of bacteria that symbiotically interact with the body.1 The gut microbiome’s interplay with the immune system makes microbiome modulation a focus for treating solid malignancies responsive to immune checkpoint inhibitors (ICIs) .2 Common strategies to modulate the gut microbiome, including prebiotics, probiotics, and fecal microbiota transplantation (FMT), have shown clinical activity in patients with advanced solid malignancies receiving ICIs. By contrast, other approaches, such as postbiotics and vitamin supplementation, have not demonstrated meaningful clinical benefit.3-5 In this review, we critically appraised studies addressing the gut microbiome modulation combined with ICIs in patients with solid malignancies. Figure 1 summarizes the main microbiome modulation approaches, their limitations, and relevant ongoing clinical trials in oncology.  \nTHE MICROBIOME AND OUTCOMES WITH ICIs  \nThe adoption of ICIs as a cornerstone treatment for various tumors has fueled growing interest in the mechanisms underlying immunotherapy resistance.6 In preclinical melanoma models, Sivan et al8 and V´etizou et al7 identified two commensal bacterial species, Bifidobacterium and Bacteroides, respectively, as potential modulators for ICI treatment  \nresponses. These discoveries paved the way for studies investigating the relationship between gut microbiome composition and patient outcomes with ICIs in solid malignancies, specifically advanced melanoma, metastatic renal cell carcinoma (mRCC), and metastatic non–small cell lung cancer (mNSCLC). Specific stool bacterial taxa, namely, Ruminococcaceae, Akkermansia, and Bifidobacterium, were associated with improved treatment responses to anti–PD-1 antibodies.9-11 Additionally, data from the PURE-01 trial of neoadjuvant pembrolizumab for muscle-invasive bladder cancer showed that the Sutterella genus was more p","cbCailf14ixMcjnX","https://ap.wps.com/l/cbCailf14ixMcjnX","pdf",370854,"English","# Abstract\n# Microbiome and outcomes with ICIs\n# Microbiome modulation approaches\n## Definition and mechanism\n## Limitations\n## Selected ongoing clinical trials","[{\"question\":\"How does gut microbiome modulation relate to immune checkpoint inhibitor outcomes in solid tumors?\",\"answer\":\"The review links gut microbiome composition to immune system behavior that influences responses to ICIs. Favorable bacterial taxa correlate with better treatment responses, while disruption can worsen outcomes.\"},{\"question\":\"Which stool bacterial groups are associated with improved clinical outcomes to ICIs?\",\"answer\":\"Ruminococcaceae, Akkermansia, and Bifidobacterium are described as correlating with favorable clinical outcomes. Additional trial data also connect genera such as Sutterella with responder status in some settings.\"},{\"question\":\"What microbiome-modulating strategies are discussed, and what limitations remain?\",\"answer\":\"The review covers fecal microbiota transplantation, probiotics, prebiotics, and related interventions, including their mechanisms. It highlights limitations such as variable responses, lack of universally accepted dosing for prebiotics, possible overgrowth of nonbeneficial bacteria, and risks tied to transplantation.\"}]","Microbiome Modulation for the Treatment of Solid Neoplasms | PDF",1790194964,15]